Cibc Asset Management Inc Aurinia Pharmaceuticals Inc. Transaction History

Cibc Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$10.93 - $23.55 $926,492 - $2 Million	-84,766 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $87,200 - $126,614	8,720 Added 11.47%	84,766 $1.1 Million
Q1 2021 May 14, 2021	BUY	$12.3 - $18.73 $22,607 - $34,425	1,838 Added 2.48%	76,046 $988,000
Q4 2020 Feb 03, 2021	BUY	$12.94 - $16.05 $89,467 - $110,969	6,914 Added 10.27%	74,208 $1.02 Million
Q3 2020 Nov 05, 2020	BUY	$13.19 - $16.66 $42,392 - $53,545	3,214 Added 5.02%	67,294 $990,000
Q2 2020 Jul 28, 2020	BUY	$14.12 - $18.33 $904,809 - $1.17 Million	64,080 New	64,080 $1.04 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.